Put the Power in their Hands

acapella® Choice Vibratory PEP Therapy System

Drug-free supplemental treatment for COPD and excessive secretions

Download Brochure
REQUEST A SAMPLE

What is Vibratory PEP?

Vibratory PEP Therapy is a drug-free supplemental treatment for COPD and excessive secretions that adds back pressure and vibrations to the patient’s expired breath.

  • Reduce air trapping, common with asthma and COPD
  • Prevent or reverse atelectasis
  • Help mobilize retained secretions related to cystic fibrosis and chronic bronchitis
  • Optimize the delivery of bronchodilators

Who Uses Vibratory PEP Therapy?

LATC

Nursing Home

Prevent COPD flare-ups and reduce readmissions.

LATC

Long Term Acute Care

Shorten length of stay and improve quality of life.

LATC

Patients at Home

Billable for HME providers and helps manage COPD flare-ups.

The Clear Choice

Allows proximal placement of a nebulizer.

Device that can be fully disassembled for easy cleaning in the facility or at home (dishwasher, boiling and autoclave safe).

Approved for use on all patients, from pediatric to adult. Achieve PEP in any position, sitting, standing or lying down.

Clinically Proven

Reduces COPD flare-ups by 28%

Retrospective review of 810 COPD patients.1Retrospective review of 810 COPD patients.1

Reduces length of stay by 1.5 days2

Patients receiving PEP or OPEP therapy with acapella saw a reduction in length of stay of 1.5 days.2

Download Brochure
Request a Sample

References:

1. Suggett J. A retrospective cohort study demonstrating the impact of an OPEP device on exacerbations in COPD patients with chronic bronchitis. European Respiratory Journal. 2016; 48. Available at: https://erj.ersjournals.com/content/48/suppl_60/PA3780. Accessed August 11, 2019.

2. Milan S, Bondalapati P, Bachman E, Weingarten JA. Use of a positive expiratory pressure device reduces hospital length of stay for acute exacerbation of chronic obstructive pulmonary disease. Presented at: American Thoracic Society International Conference; May 13-18, 2016; San Francisco, CA.